News headlines about Endologix (NASDAQ:ELGX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endologix earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 45.9707742771269 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities research analysts have commented on the company. Canaccord Genuity reissued a “hold” rating and issued a $5.00 target price on shares of Endologix in a report on Wednesday, November 8th. Piper Jaffray Companies reissued an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. ValuEngine downgraded Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Royal Bank of Canada reissued a “hold” rating and issued a $5.00 target price on shares of Endologix in a report on Tuesday, October 3rd. Finally, BidaskClub downgraded Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $5.41.
Endologix (ELGX) opened at $4.59 on Friday. Endologix has a one year low of $4.08 and a one year high of $7.66. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. The firm has a market capitalization of $383.05, a price-to-earnings ratio of -4.94 and a beta of 0.72.
TRADEMARK VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/endologix-elgx-receives-news-sentiment-rating-of-0-21.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.